71582 Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices 

Date: November 16–17, 2023. 

Time: 9:30 a.m. to 7:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Joonil Seog, SCD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, 301–402–9791, joonil.seog@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Computational, Modeling, and 

Biodata Management. 

Date: November 16, 2023. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Marie-Jose Belanger, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm 6188, MSC 

7804, Bethesda, MD 20892, 301–435–1267, 

belangerm@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 12, 2023. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22859 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Advancing 

Translational Sciences; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Advancing Translational Sciences Special 

Emphasis Panel; Botulinum Toxin Potency 

Assay using Tissue Chips. 

Date: November 20, 2023. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Center for Advancing 

Translational Sciences, National Institutes of 

Health, One Democracy Plaza, 6701 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Rahat (Rani) Khan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, National Center for Advancing 

Translational Sciences, National Institutes of 

Health, 6701 Democracy Boulevard, Room 

1078, Bethesda, MD 20892, 301–594–7319, 

khanr2@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.859, Pharmacology, 

Physiology, and Biological Chemistry 

Research; 93.350, B—Cooperative 

Agreements; 93.859, Biomedical Research 

and Research Training, National Institutes of 

Health, HHS) 

Dated: October 12, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22858 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN Initiative: Centers for Engineering 

Molecular Technologies for Functional 

Dissection of Neural Circuits (UM1). 

Date: November 17, 2023. 

Time: 10:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Jasenka Borzan, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

6001 Executive Blvd., Neuroscience Center, 

Bethesda, MD 20892, 301–435–1260, 

jasenka.borzan@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.242, Mental Health Research 

Grants, National Institutes of Health, HHS) 

Dated: October 11, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–22804 Filed 10–16–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Notice of Meeting 

Pursuant to Public Law 92–463, 

notice is hereby given that the 

Substance Abuse and Mental Health 

Services Administration’s (SAMHSA) 

Center for Substance Abuse Prevention’s 

(CSAP) Drug Testing Advisory Board 

(DTAB) will convene via web 

conference on December 5, 2023, from 

10 a.m. EST to 4:30 p.m. 

The board will meet in open-session 

December 5, 2023, from 10 a.m. EST to 

4:30 p.m. EST to hear Federal Partner 

updates and presentations regarding 

NLCP activities, updates to the MRO 

manuals, lab created cannabinoids and 

other contaminants in commercially 

available products and the process for 

adding or removing analytes from the 

analyte table for federally regulated 

testing. The board will discuss the 

Mandatory Guidelines for Federal 

Workplace Drug Testing Programs and 

updates to the analyte table to include 

Fentanyl. Additionally the Department 

is asking for public comments on the 

recommendation of adding fentanyl/ 

nor-fentanyl to the analyte table. 

Section 8105 of the Fighting Opioid 

Abuse in Transportation Act, included 

in the SUPPORT for Patients and 

Communities Act, required the 

Secretary to determine whether it is 

justified, based on the reliability and 

cost-effectiveness of testing, to revise 

the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs to 

include fentanyl. Section 8105 

additionally required the Secretary to 

consider whether to include any other 

drugs or other substances listed in 

Schedule I and II of Controlled 

Substances Act (CSA). Norfentanyl is a 

metabolite of fentanyl. Because it is also 

an immediate precursor used in the 

illicit manufacture of fentanyl, it is a 

Schedule II substance under the CSA. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 199 / Tuesday, October 17, 2023 / Notices 71583 

1National Forensic Laboratory Information 

System (NFLIS). (2021). NFLIS-Drug 2021 Annual 

Report. U.S. Department of Justice, Drug 

Enforcement Agency, Diversion Control Division. 

https://www.nflis.deadiversion.usdoj.gov/. 

Fentanyl accounts for a large 

proportion of overdose deaths in the 

United States and is therefore an 

important public safety concern. 

Furthermore, fentanyl is increasingly 

used as a stand-alone substance of 

abuse, not in conjunction with heroin 

and other substances. According to the 

National Forensic Laboratory 

Information System (NFLIS) 2021 

report, fentanyl was the 4th most 

frequently identified drug and 

accounted for 11.61% of all drugs 

reported by forensic laboratories.1

Norfentanyl is an important component 

of identifying fentanyl users when urine 

is the specimen matrix. Fentanyl has 

been detected in oral fluid in pain 

management patients, overdose cases, 

and driving under the influence of drugs 

(DUID) cases. Information provided by 

HHS-certified laboratories in 2023 

indicated that a majority (84%) of the 

laboratories analyzed non-regulated 

workplace specimens for fentanyl and/ 

or norfentanyl, and that all had the 

ability to analyze urine specimens for 

fentanyl with sufficiently sensitive 

detection limits using commercially 

available immunoassay kits and 

confirmatory test instrumentation 

commonly used in HHS-certified 

laboratories. 

The Division of Workplace Programs 

welcomes public comment prior to the 

DTAB meeting regarding the possible 

addition of Fentanyl to the Urine and 

Oral Fluid Analyte Table. Please see 

below for the process to submit 

comments. 

Addition to HHS Drug Testing Panels 

as listed below: 

Initial 

test 

cutoff 

Confirmation 

cutoff 

Urine Analyte: 

Fentanyl ............ 1 ng/mL 0.5 ng/mL. 

Norfentanyl ........ 1 ng/mL 0.5 ng/mL. 

Oral Fluid Analyte: 

Fentanyl ............ 1 ng/mL 0.5 ng/mL. 

Meeting registration information can 

be completed at https://snacregister.

samhsa.gov/. Web conference and call 

information will be sent after 

completing registration. Meeting 

information and a roster of DTAB 

members may be obtained by accessing 

the SAMHSA Advisory Committees 

website, https://www.samhsa.gov/ 

about-us/advisory-councils/meetings, or 

by contacting the Designated Federal 

Officer, Lisa Davis. 

Committee Name: Substance Abuse 

and Mental Health Services 

Administration, Center for Substance 

Abuse Prevention, Drug Testing 

Advisory Board. 

Dates/Time/Type: December 5, 2023, 

from 10 a.m. EST to 4:30 p.m. EST: 

OPEN. 

Place: Virtual. 

To Submit Comments: Requests to 

make public comment during the public 

comment period of the December DTAB 

meeting must be made in writing at least 

7 days prior to the meeting to the 

following email: DFWP@

samhsa.hhs.gov. 

Please submit written comments 

regarding the addition of Fentanyl to the 

analyte table to the following email: 

DFWP@samhsa.hhs.gov. 

Comments regarding the addition of 

Fentanyl to the analyte table will be 

accepted for review for an additional 30 

days following this meeting, or no later 

than January 4th, 2024. 

Contact: Lisa S. Davis, M.S., Social 

Science Analyst, Center for Substance 

Abuse Prevention, 5600 Fishers Lane, 

Rockville, Maryland 20857, Telephone: 

(240) 276–1440, Email: Lisa.Davis@

samhsa.hhs.gov. 

Anastasia Flanagan, 

Public Health Advisor, Division of Workplace 

Programs. 

[FR Doc. 2023–22797 Filed 10–16–23; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

U.S. Customs and Border Protection 

[OMB Control Number 1651–0021] 

Agency Information Collection 

Activities; Extension of Existing 

Collection; Crew Member’s Declaration 

CBP (Form 5129) 

AGENCY: U.S. Customs and Border 

Protection (CBP), Department of 

Homeland Security. 

ACTION: 60-Day notice and request for 

comments. 

SUMMARY: The Department of Homeland 

Security, U.S. Customs and Border 

Protection (CBP) will be submitting the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995 (PRA). The 

information collection is published in 

the Federal Register to obtain comments 

from the public and affected agencies. 

DATES: Comments are encouraged and 

must be submitted (no later than 

December 18, 2023) to be assured of 

consideration. 

ADDRESSES: Written comments and/or 

suggestions regarding the item(s) 

contained in this notice must include 

the OMB Control Number 1651–0021 in 

the subject line and the agency name. 

Please use the following method to 

submit comments: 

Email. Submit comments to: CBP_

PRA@cbp.dhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional PRA information 

should be directed to Seth Renkema, 

Chief, Economic Impact Analysis 

Branch, U.S. Customs and Border 

Protection, Office of Trade, Regulations 

and Rulings, 90 K Street NE, 10th Floor, 

Washington, DC 20229–1177, telephone 

number 202–325–0056 or via email 

CBP_PRA@cbp.dhs.gov. Please note that 

the contact information provided here is 

solely for questions regarding this 

notice. Individuals seeking information 

about other CBP programs should 

contact the CBP National Customer 

Service Center at 877–227–5511, (TTY) 

1–800–877–8339, or CBP website at 

https://www.cbp.gov/. 

SUPPLEMENTARY INFORMATION: CBP 

invites the general public and other 

Federal agencies to comment on the 

proposed and/or continuing information 

collections pursuant to the Paperwork 

Reduction Act of 1995 (44 U.S.C. 3501 

et seq.). This process is conducted in 

accordance with 5 CFR 1320.8. Written 

comments and suggestions from the 

public and affected agencies should 

address one or more of the following 

four points: (1) whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; (2) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

suggestions to enhance the quality, 

utility, and clarity of the information to 

be collected; and (4) suggestions to 

minimize the burden of the collection of 

information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology, e.g., permitting 

electronic submission of responses. The 

comments that are submitted will be 

summarized and included in the request 

for approval. All comments will become 

a matter of public record. 


lotter on DSK11XQN23PROD with NOTICES1